LANNETT ANNOUNCES SUBMISSION OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR BIOSIMILAR INSULIN GLARGINE
- Monday, December 20, 2021, 7:09
- Finance
- Add a comment
PHILADELPHIA, Dec. 20, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the pivotal clinical trial of biosimilar insulin glargine, a product the…
About the Author
adminasapcorp has written 41677 stories on this site.